Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:ALIOF
- CUSIP: N/A
- Web: www.actelion.com
Capitalization:- Market Cap: $29.14 billion
- Outstanding Shares: 104,638,000
Average Prices:- 50 Day Moving Avg: $280.30
- 200 Day Moving Avg: $260.56
- 52 Week Range: $138.01 - $286.30
P/E:- Trailing P/E Ratio: 40.59
- Foreward P/E Ratio: 31.97
- P/E Growth: 2.61
Sales & Book Value:- Annual Revenue: $2.54 billion
- Price / Sales: 11.47
- Book Value: $15.84 per share
- Price / Book: 17.58
Dividend:
Profitability:- EBIDTA: $945.69 million
- Net Margins: 28.89%
- Return on Equity: 53.21%
- Return on Assets: 35.24%
Debt:- Current Ratio: 2.76%
- Quick Ratio: 2.51%
Misc:- Average Volume: 647 shs.
- Beta: 1.52
Frequently Asked Questions for Actelion (OTCMKTS:ALIOF)
What is Actelion's stock symbol?
Actelion trades on the OTCMKTS under the ticker symbol "ALIOF."
How were Actelion's earnings last quarter?
Actelion Ltd. (OTCMKTS:ALIOF) posted its earnings results on Monday, February, 16th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The business had revenue of $501.50 million for the quarter, compared to the consensus estimate of $546.30 million. Actelion had a return on equity of 53.21% and a net margin of 28.89%. View Actelion's Earnings History.
Who are some of Actelion's key competitors?
Some companies that are related to Actelion include Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Stryker Corporation (SYK), Aetna (AET), Anthem (ANTM), Fresenius SE (FSNUY), Becton, Dickinson and Company (BDX), Takeda Pharmaceutical (TKPYY), Express Scripts Holding Company (ESRX), Boston Scientific Corporation (BSX), McKesson Corporation (MCK), Intuitive Surgical (ISRG), Humana (HUM), Teva Pharmaceutical Industries Limited (TEVA), Baxter International (BAX), Vertex Pharmaceuticals Incorporated (VRTX), HCA Holdings (HCA) and Zoetis (ZTS).
Who are Actelion's key executives?
Actelion's management team includes the folowing people:
- Jean-Pierre Garnier Ph.D., Chairman of the Board of Directors
- Jean-Paul Clozel, Chief Executive Officer, Member of the Executive Committee, Delegate of the Board of Directors
- Thomas Widman, Co-Founder
- Andre C. Muller, Chief Financial Officer, Executive Vice President, Member of the Executive Committee
- Otto Schwarz, Chief Operating Officer, Executive Vice President, Member of the Executive Committee
- Guy Braunstein, Executive Vice President, Head of Global Clinical Development, Member of the Executive Committee
- Nicholas Franco, Executive Vice President, Chief Business Development Officer, Member of the Executive Committee
- Martine Clozel, Senior Vice President, Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Actelion Executive Committee
- Marian Borovsky, Senior Vice President, Group General Counsel, Member of the Extended Actelion Executive Committee, Corporate Secretary to the Board of Directors
- Christian Albrich, Senior Vice President, Head Global Human Resources, Member of the Extended Actelion Executive Committee
How do I buy Actelion stock?
Shares of Actelion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Actelion's stock price today?
One share of Actelion stock can currently be purchased for approximately $278.50.
MarketBeat Community Rating for Actelion (OTCMKTS ALIOF)MarketBeat's community ratings are surveys of what our community members think about Actelion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Actelion (OTCMKTS:ALIOF) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Actelion (OTCMKTS:ALIOF)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 3/8/2017 | J P Morgan Chase & Co | Upgrade | Neutral -> Overweight | |  |
| 1/5/2017 | Jefferies Group LLC | Downgrade | Buy -> Hold | | |
(Data available from 6/28/2015 forward)
Earnings History for Actelion (OTCMKTS:ALIOF)Earnings History by Quarter for Actelion (OTCMKTS ALIOF)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/20/2016 | Q3 2016 | $2.12 | $2.39 | $603.47 million | $626.61 million | View | N/A | |
| 10/20/2015 | Q3 2015 | $1.61 | $1.90 | $527.94 million | $533.07 million | View | N/A | |
| 4/21/2015 | Q1 2015 | $1.28 | $1.68 | $506.91 million | $539.65 million | View | N/A | |
| 2/16/2015 | Q4 2014 | $1.09 | $0.87 | $546.30 million | $501.50 million | View | N/A | |
| 10/21/2014 | Q3 2014 | $1.50 | $1.61 | $511.25 million | $525.03 million | View | N/A | |
| 7/22/2014 | Q2 2014 | $1.37 | $2.00 | $516.67 million | $583.43 million | View | N/A | |
| 4/17/2014 | Q1 2014 | $1.12 | $1.65 | $504.04 million | $531.17 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Actelion (OTCMKTS:ALIOF)Current Year EPS Consensus Estimate: $7.76 EPS
Next Year EPS Consensus Estimate: $8.71 EPS
Dividend History for Actelion (OTCMKTS:ALIOF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Actelion (OTCMKTS:ALIOF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Actelion (OTCMKTS:ALIOF)
Latest Headlines for Actelion (OTCMKTS:ALIOF)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Actelion Ltd. : June 19, 2017
finance.yahoo.com - June 19 at 3:30 PM |
| Actelion spin-off Idorsia's shares rise 30 pct in market debut
finance.yahoo.com - June 16 at 4:05 PM |
| Actelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 4:05 PM |
| Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : June 15, 2017
finance.yahoo.com - June 15 at 5:02 PM |
| Johnson & Johnson Stock Just Hit an All-Time High: Here's Why It Could Go Higher
finance.yahoo.com - June 11 at 3:27 PM |
| Johnson & Johnson Moves Forward with Actelion Purchase After EU Approval
finance.yahoo.com - June 9 at 3:41 PM |
| Actelion Ltd. – Value Analysis (US OTC:ALIOF) : May 2, 2017
finance.yahoo.com - May 3 at 8:11 AM |
| Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : May 1, 2017
finance.yahoo.com - May 1 at 9:44 AM |
 | Janssen Holding Acquires 92.51% Of Actelion
www.nasdaq.com - April 25 at 3:26 PM |
| Here's Why Risk-Averse Investors May Want to Think Twice About Buying Johnson & Johnson
finance.yahoo.com - April 25 at 3:26 PM |
| Johnson & Johnson Announces Interim Result For Actelion Tender Offer
www.nasdaq.com - March 31 at 1:54 AM |
| J&J declares Actelion tender offer a success, sees closing in Q2
finance.yahoo.com - March 31 at 1:54 AM |
| J&J declares Actelion tender offer a success, sees closing in second quarter
finance.yahoo.com - March 31 at 1:54 AM |
 | Actelion Ltd (ALIOF) Raised to Overweight at JPMorgan Chase & Co.
www.americanbankingnews.com - March 8 at 12:35 PM |
| United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
finance.yahoo.com - February 23 at 3:28 PM |
 | Actelion FY16 Profit Rises
www.rttnews.com - February 14 at 1:56 AM |
 | Just 2 of the 13 Largest Drugmakers Have More Cash Than Debt -- Can You Guess Who They Are?
www.fool.com - February 8 at 3:37 PM |
| Johnson & Johnson May Never Recoup Its Costs to Buy Actelion
www.fool.com - February 4 at 1:41 AM |
| J&J to Acquire Actelion for $30B: Is It a Strategic Fit?
finance.yahoo.com - January 27 at 3:35 PM |
| Johnson & Johnson To Buy Actelion For $30 Bln With Spin-out Of New R&D Company
www.nasdaq.com - January 26 at 8:45 PM |
| Actelion Stock Up On $30 Bln Takeover Deal With JNJ; To Spin-Out R&D To New Firm
www.rttnews.com - January 26 at 8:45 PM |
 | [$$] J&J/Actelion: high pressure sale
us.rd.yahoo.com - January 26 at 3:43 PM |
 | [$$] Johnson & Johnson to buy Swiss biotech company Actelion for $30bn
www.ft.com - January 26 at 3:43 PM |
| [$$] J&J digs deep to claim its $30bn Actelion prize
www.ft.com - January 26 at 3:43 PM |
 | Johnson & Johnson (JNJ) Stock Could Win BIG After Actelion Purchase
investorplace.com - January 26 at 12:15 PM |
 | Actelion Founder's $1.5 Billion Payday Gives Him Shot at More - Bloomberg
www.bloomberg.com - January 26 at 12:11 PM |
 | Europe Markets: European stocks hang at 1-year high, buoyed by Actelion and bank shares
www.marketwatch.com - January 26 at 6:05 AM |
| J&J Seals $30 Billion Actelion Deal to Enter Rare Disease Arena - Bloomberg
www.bloomberg.com - January 26 at 4:39 AM |
| [$$] Novartis: buying time
www.ft.com - January 25 at 3:32 PM |
 | Johnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings
us.rd.yahoo.com - January 24 at 8:49 PM |
| J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit
finance.yahoo.com - January 24 at 3:48 PM |
| [$$] J&J disappoints on 2017 forecasts due to strong dollar
www.ft.com - January 24 at 3:48 PM |
| Johnson & Johnson CEO Talks Trump, M&A After Mixed Earnings
www.thestreet.com - January 24 at 3:48 PM |
| 5 Best Performing Healthcare Mutual Funds of 2016
finance.yahoo.com - January 23 at 3:29 PM |
 | VIVUS Licenses Rights to PAH Drugs from Selten Pharma
www.zacks.com - January 11 at 3:45 PM |
| 4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
finance.yahoo.com - January 10 at 3:29 PM |
| United Therapeutics' PAH Suite Bodes Well, Competition Rife
finance.yahoo.com - December 29 at 3:29 PM |
| J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?
finance.yahoo.com - December 22 at 3:26 PM |
| [$$] Actelion/J&J: hypertension tactics
www.ft.com - December 22 at 3:26 PM |
 | Wall Street's M&A Chatter From December 21
feeds.benzinga.com - December 22 at 7:27 AM |
| [$$] Johnson & Johnson and Actelion disclose 'exclusive' deal talks
www.ft.com - December 21 at 4:28 PM |
| European Stocks Drift Lower; Dollar Dominates Global Financial Markets
us.rd.yahoo.com - December 16 at 3:33 PM |
| 5 Things You Must Know Before the Market Opens Friday
us.rd.yahoo.com - December 16 at 3:33 PM |
 | Actelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the treatment of MF-CTCL
us.rd.yahoo.com - December 16 at 3:33 PM |
| Johnson & Johnson Looks for New Deal That's Just Right
us.rd.yahoo.com - December 15 at 3:52 PM |
| Actelion's Independent Streak Gives Rise to Doubt That Sanofi Will Fill the Breach
us.rd.yahoo.com - December 14 at 8:43 PM |
| [$$] Actelion: PAH, humbug
us.rd.yahoo.com - December 14 at 8:43 PM |
| J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?
www.nasdaq.com - December 14 at 3:39 PM |
| [$$] Sanofi in talks to acquire biotech Actelion as J&J bows out
www.ft.com - December 14 at 1:31 AM |
| Actelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP
www.thestreet.com - December 7 at 4:06 PM |
Actelion (ALIOF) Chart for Wednesday, June, 28, 2017
